Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Stanulla

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
Seminars in Hematology|December 23, 2008
Treatment of childhood acute lymphoblastic leukemiaMartin Stanulla, Martin Schrappe
Blood|December 11, 2019
IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?Martin Stanulla, Hélène Cavé, Anthony V Moorman
European Journal of Medical Genetics|December 25, 2015
Genetic predisposition to acute lymphoblastic leukemia: Overview on behalf of the I-BFM ALL Host Genetic Variation Working GroupChristian Peter Kratz, Martin Stanulla, Hélène Cavé
BMC Blood Disorders|April 25, 2001
Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapyMartin Stanulla, André Schrauder, Karl Welte, et al.
Interface Focus|December 30, 2017
A study on the predictability of acute lymphoblastic leukaemia response to treatment using a hybrid oncosimulatorEleftherios Ouzounoglou, Eleni Kolokotroni, Martin Stanulla, et al.
Seminars in Hematology|June 28, 2008
Misconceptions, challenges, uncertainty, and progress in guideline recommendationsRegina Kunz, Benjamin Djulbegovic, Holger J Schunemann, et al.
Annals of Hematology|June 4, 2008
Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemiaGunnar Cario, Andrea Fetz, Christian Bretscher, et al.
Blood Cells, Molecules & Diseases|May 29, 2007
Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study GroupMartin Stanulla, Gunnar Cario, Barbara Meissner, et al.
Annals of Hematology|February 8, 2006
MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95Kathrin Seidemann, Marion Book, Martin Zimmermann, et al.
International Journal of Hematology|April 9, 2009
Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control studyEkaterini Kidas, Anja Möricke, Rita Beier, et al.
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
Seminars in Hematology|December 23, 2008
Treatment of childhood acute lymphoblastic leukemiaMartin Stanulla, Martin Schrappe
Blood|December 11, 2019
IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?Martin Stanulla, Hélène Cavé, Anthony V Moorman
European Journal of Medical Genetics|December 25, 2015
Genetic predisposition to acute lymphoblastic leukemia: Overview on behalf of the I-BFM ALL Host Genetic Variation Working GroupChristian Peter Kratz, Martin Stanulla, Hélène Cavé
BMC Blood Disorders|April 25, 2001
Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapyMartin Stanulla, André Schrauder, Karl Welte, et al.
Interface Focus|December 30, 2017
A study on the predictability of acute lymphoblastic leukaemia response to treatment using a hybrid oncosimulatorEleftherios Ouzounoglou, Eleni Kolokotroni, Martin Stanulla, et al.
Seminars in Hematology|June 28, 2008
Misconceptions, challenges, uncertainty, and progress in guideline recommendationsRegina Kunz, Benjamin Djulbegovic, Holger J Schunemann, et al.
Annals of Hematology|June 4, 2008
Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemiaGunnar Cario, Andrea Fetz, Christian Bretscher, et al.
Blood Cells, Molecules & Diseases|May 29, 2007
Integrating molecular information into treatment of childhood acute lymphoblastic leukemia--a perspective from the BFM Study GroupMartin Stanulla, Gunnar Cario, Barbara Meissner, et al.
Annals of Hematology|February 8, 2006
MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95Kathrin Seidemann, Marion Book, Martin Zimmermann, et al.
International Journal of Hematology|April 9, 2009
Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control studyEkaterini Kidas, Anja Möricke, Rita Beier, et al.
Pageof 15